nodes	percent_of_prediction	percent_of_DWPC	metapath
Irinotecan—Topoisomerase Inhibitors—Epirubicin—bone cancer	0.245	0.519	CiPCiCtD
Irinotecan—Topoisomerase Inhibitors—Doxorubicin—bone cancer	0.227	0.481	CiPCiCtD
Irinotecan—breast cancer—bone cancer	0.167	0.606	CtDrD
Irinotecan—lung cancer—bone cancer	0.108	0.394	CtDrD
Irinotecan—CYP3A4—bone cancer	0.0678	1	CbGaD
Irinotecan—ABCC1—Epirubicin—bone cancer	0.0155	0.117	CbGbCtD
Irinotecan—BCHE—Cisplatin—bone cancer	0.0117	0.0885	CbGbCtD
Irinotecan—ABCC2—Carboplatin—bone cancer	0.0107	0.0807	CbGbCtD
Irinotecan—ABCG2—Carboplatin—bone cancer	0.00965	0.0729	CbGbCtD
Irinotecan—ABCC2—Cisplatin—bone cancer	0.00913	0.0689	CbGbCtD
Irinotecan—ABCC1—Doxorubicin—bone cancer	0.00826	0.0624	CbGbCtD
Irinotecan—ABCG2—Cisplatin—bone cancer	0.00825	0.0623	CbGbCtD
Irinotecan—ABCC1—Methotrexate—bone cancer	0.008	0.0605	CbGbCtD
Irinotecan—SLCO1B1—Methotrexate—bone cancer	0.00674	0.0509	CbGbCtD
Irinotecan—ABCC2—Doxorubicin—bone cancer	0.00612	0.0462	CbGbCtD
Irinotecan—ABCC2—Methotrexate—bone cancer	0.00592	0.0447	CbGbCtD
Irinotecan—CYP2B6—Cisplatin—bone cancer	0.0058	0.0438	CbGbCtD
Irinotecan—ABCG2—Doxorubicin—bone cancer	0.00553	0.0418	CbGbCtD
Irinotecan—ABCG2—Methotrexate—bone cancer	0.00536	0.0405	CbGbCtD
Irinotecan—CYP2B6—Doxorubicin—bone cancer	0.00389	0.0294	CbGbCtD
Irinotecan—ALB—Methotrexate—bone cancer	0.00369	0.0279	CbGbCtD
Irinotecan—ABCB1—Cisplatin—bone cancer	0.00297	0.0225	CbGbCtD
Irinotecan—ABCB1—Doxorubicin—bone cancer	0.00199	0.0151	CbGbCtD
Irinotecan—ABCB1—Methotrexate—bone cancer	0.00193	0.0146	CbGbCtD
Irinotecan—CYP3A4—Doxorubicin—bone cancer	0.00119	0.00902	CbGbCtD
Irinotecan—Topotecan—CYP3A4—bone cancer	0.000855	1	CrCbGaD
Irinotecan—Osteoarthritis—Methotrexate—bone cancer	6.43e-05	0.00188	CcSEcCtD
Irinotecan—Blood alkaline phosphatase increased—Doxorubicin—bone cancer	6.4e-05	0.00187	CcSEcCtD
Irinotecan—Dermatitis exfoliative—Epirubicin—bone cancer	6.38e-05	0.00187	CcSEcCtD
Irinotecan—Malaise—Cisplatin—bone cancer	6.37e-05	0.00186	CcSEcCtD
Irinotecan—Renal impairment—Epirubicin—bone cancer	6.33e-05	0.00185	CcSEcCtD
Irinotecan—Leukopenia—Cisplatin—bone cancer	6.32e-05	0.00185	CcSEcCtD
Irinotecan—Anaphylactoid reaction—Epirubicin—bone cancer	6.22e-05	0.00182	CcSEcCtD
Irinotecan—Cerebrovascular accident—Epirubicin—bone cancer	6.14e-05	0.0018	CcSEcCtD
Irinotecan—Hyponatraemia—Epirubicin—bone cancer	6.04e-05	0.00177	CcSEcCtD
Irinotecan—Renal failure acute—Doxorubicin—bone cancer	6.03e-05	0.00176	CcSEcCtD
Irinotecan—Osteoarthritis—Epirubicin—bone cancer	6.02e-05	0.00176	CcSEcCtD
Irinotecan—Gastrointestinal haemorrhage—Epirubicin—bone cancer	6.02e-05	0.00176	CcSEcCtD
Irinotecan—Discomfort—Cisplatin—bone cancer	5.94e-05	0.00174	CcSEcCtD
Irinotecan—Dermatitis exfoliative—Doxorubicin—bone cancer	5.9e-05	0.00173	CcSEcCtD
Irinotecan—Renal impairment—Doxorubicin—bone cancer	5.85e-05	0.00171	CcSEcCtD
Irinotecan—Oedema—Cisplatin—bone cancer	5.76e-05	0.00169	CcSEcCtD
Irinotecan—Anaphylactic shock—Cisplatin—bone cancer	5.76e-05	0.00169	CcSEcCtD
Irinotecan—Anaphylactoid reaction—Doxorubicin—bone cancer	5.75e-05	0.00168	CcSEcCtD
Irinotecan—Cardiac arrest—Epirubicin—bone cancer	5.72e-05	0.00167	CcSEcCtD
Irinotecan—Infection—Cisplatin—bone cancer	5.72e-05	0.00167	CcSEcCtD
Irinotecan—Cerebrovascular accident—Doxorubicin—bone cancer	5.68e-05	0.00166	CcSEcCtD
Irinotecan—Nervous system disorder—Cisplatin—bone cancer	5.65e-05	0.00165	CcSEcCtD
Irinotecan—Thrombocytopenia—Cisplatin—bone cancer	5.64e-05	0.00165	CcSEcCtD
Irinotecan—Blood creatinine increased—Epirubicin—bone cancer	5.64e-05	0.00165	CcSEcCtD
Irinotecan—Dehydration—Epirubicin—bone cancer	5.6e-05	0.00164	CcSEcCtD
Irinotecan—Hyponatraemia—Doxorubicin—bone cancer	5.59e-05	0.00164	CcSEcCtD
Irinotecan—Osteoarthritis—Doxorubicin—bone cancer	5.57e-05	0.00163	CcSEcCtD
Irinotecan—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	5.57e-05	0.00163	CcSEcCtD
Irinotecan—Hyperhidrosis—Cisplatin—bone cancer	5.57e-05	0.00163	CcSEcCtD
Irinotecan—Orthostatic hypotension—Epirubicin—bone cancer	5.5e-05	0.00161	CcSEcCtD
Irinotecan—Anorexia—Cisplatin—bone cancer	5.49e-05	0.00161	CcSEcCtD
Irinotecan—Hypokalaemia—Epirubicin—bone cancer	5.48e-05	0.0016	CcSEcCtD
Irinotecan—Pancreatitis—Methotrexate—bone cancer	5.45e-05	0.00159	CcSEcCtD
Irinotecan—Aspartate aminotransferase increased—Epirubicin—bone cancer	5.42e-05	0.00159	CcSEcCtD
Irinotecan—Hypotension—Cisplatin—bone cancer	5.38e-05	0.00157	CcSEcCtD
Irinotecan—Cardiac arrest—Doxorubicin—bone cancer	5.3e-05	0.00155	CcSEcCtD
Irinotecan—Abdominal distension—Epirubicin—bone cancer	5.24e-05	0.00153	CcSEcCtD
Irinotecan—Blood creatinine increased—Doxorubicin—bone cancer	5.22e-05	0.00153	CcSEcCtD
Irinotecan—Neutropenia—Methotrexate—bone cancer	5.2e-05	0.00152	CcSEcCtD
Irinotecan—Dehydration—Doxorubicin—bone cancer	5.18e-05	0.00152	CcSEcCtD
Irinotecan—Paraesthesia—Cisplatin—bone cancer	5.17e-05	0.00151	CcSEcCtD
Irinotecan—Upper respiratory tract infection—Methotrexate—bone cancer	5.17e-05	0.00151	CcSEcCtD
Irinotecan—Dyspnoea—Cisplatin—bone cancer	5.14e-05	0.0015	CcSEcCtD
Irinotecan—Pancreatitis—Epirubicin—bone cancer	5.1e-05	0.00149	CcSEcCtD
Irinotecan—Orthostatic hypotension—Doxorubicin—bone cancer	5.09e-05	0.00149	CcSEcCtD
Irinotecan—Hypokalaemia—Doxorubicin—bone cancer	5.07e-05	0.00148	CcSEcCtD
Irinotecan—Angina pectoris—Epirubicin—bone cancer	5.07e-05	0.00148	CcSEcCtD
Irinotecan—Aspartate aminotransferase increased—Doxorubicin—bone cancer	5.02e-05	0.00147	CcSEcCtD
Irinotecan—Decreased appetite—Cisplatin—bone cancer	5.01e-05	0.00147	CcSEcCtD
Irinotecan—Pneumonia—Methotrexate—bone cancer	4.99e-05	0.00146	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Cisplatin—bone cancer	4.97e-05	0.00145	CcSEcCtD
Irinotecan—Pain—Cisplatin—bone cancer	4.93e-05	0.00144	CcSEcCtD
Irinotecan—Renal failure—Methotrexate—bone cancer	4.87e-05	0.00143	CcSEcCtD
Irinotecan—Neutropenia—Epirubicin—bone cancer	4.87e-05	0.00142	CcSEcCtD
Irinotecan—Abdominal distension—Doxorubicin—bone cancer	4.85e-05	0.00142	CcSEcCtD
Irinotecan—Upper respiratory tract infection—Epirubicin—bone cancer	4.84e-05	0.00141	CcSEcCtD
Irinotecan—Stomatitis—Methotrexate—bone cancer	4.83e-05	0.00141	CcSEcCtD
Irinotecan—Sweating—Methotrexate—bone cancer	4.75e-05	0.00139	CcSEcCtD
Irinotecan—Feeling abnormal—Cisplatin—bone cancer	4.75e-05	0.00139	CcSEcCtD
Irinotecan—Pancreatitis—Doxorubicin—bone cancer	4.72e-05	0.00138	CcSEcCtD
Irinotecan—Weight decreased—Epirubicin—bone cancer	4.71e-05	0.00138	CcSEcCtD
Irinotecan—Angina pectoris—Doxorubicin—bone cancer	4.69e-05	0.00137	CcSEcCtD
Irinotecan—Pneumonia—Epirubicin—bone cancer	4.67e-05	0.00136	CcSEcCtD
Irinotecan—ACHE—ATF-2 transcription factor network—CDK4—bone cancer	4.65e-05	0.00252	CbGpPWpGaD
Irinotecan—Renal failure—Epirubicin—bone cancer	4.56e-05	0.00133	CcSEcCtD
Irinotecan—Body temperature increased—Cisplatin—bone cancer	4.55e-05	0.00133	CcSEcCtD
Irinotecan—Stomatitis—Epirubicin—bone cancer	4.52e-05	0.00132	CcSEcCtD
Irinotecan—Jaundice—Epirubicin—bone cancer	4.52e-05	0.00132	CcSEcCtD
Irinotecan—Neutropenia—Doxorubicin—bone cancer	4.5e-05	0.00132	CcSEcCtD
Irinotecan—Upper respiratory tract infection—Doxorubicin—bone cancer	4.47e-05	0.00131	CcSEcCtD
Irinotecan—Haemoglobin—Methotrexate—bone cancer	4.47e-05	0.00131	CcSEcCtD
Irinotecan—Haemorrhage—Methotrexate—bone cancer	4.45e-05	0.0013	CcSEcCtD
Irinotecan—Sweating—Epirubicin—bone cancer	4.45e-05	0.0013	CcSEcCtD
Irinotecan—UGT1A1—Phase II conjugation—GSTP1—bone cancer	4.42e-05	0.0024	CbGpPWpGaD
Irinotecan—UGT1A9—Phase II conjugation—GSTP1—bone cancer	4.42e-05	0.0024	CbGpPWpGaD
Irinotecan—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	4.37e-05	0.00237	CbGpPWpGaD
Irinotecan—Weight decreased—Doxorubicin—bone cancer	4.36e-05	0.00127	CcSEcCtD
Irinotecan—Pneumonia—Doxorubicin—bone cancer	4.32e-05	0.00126	CcSEcCtD
Irinotecan—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	4.31e-05	0.00234	CbGpPWpGaD
Irinotecan—Visual impairment—Methotrexate—bone cancer	4.29e-05	0.00125	CcSEcCtD
Irinotecan—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	4.27e-05	0.00231	CbGpPWpGaD
Irinotecan—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	4.27e-05	0.00231	CbGpPWpGaD
Irinotecan—Hypersensitivity—Cisplatin—bone cancer	4.24e-05	0.00124	CcSEcCtD
Irinotecan—Bradycardia—Epirubicin—bone cancer	4.24e-05	0.00124	CcSEcCtD
Irinotecan—Renal failure—Doxorubicin—bone cancer	4.22e-05	0.00123	CcSEcCtD
Irinotecan—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	4.22e-05	0.00228	CbGpPWpGaD
Irinotecan—Haemoglobin—Epirubicin—bone cancer	4.19e-05	0.00122	CcSEcCtD
Irinotecan—Jaundice—Doxorubicin—bone cancer	4.18e-05	0.00122	CcSEcCtD
Irinotecan—Stomatitis—Doxorubicin—bone cancer	4.18e-05	0.00122	CcSEcCtD
Irinotecan—Rhinitis—Epirubicin—bone cancer	4.17e-05	0.00122	CcSEcCtD
Irinotecan—Haemorrhage—Epirubicin—bone cancer	4.16e-05	0.00122	CcSEcCtD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	4.16e-05	0.00225	CbGpPWpGaD
Irinotecan—Asthenia—Cisplatin—bone cancer	4.13e-05	0.00121	CcSEcCtD
Irinotecan—Cardiac disorder—Methotrexate—bone cancer	4.13e-05	0.00121	CcSEcCtD
Irinotecan—Sweating—Doxorubicin—bone cancer	4.11e-05	0.0012	CcSEcCtD
Irinotecan—Connective tissue disorder—Epirubicin—bone cancer	4.09e-05	0.0012	CcSEcCtD
Irinotecan—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	4.09e-05	0.00222	CbGpPWpGaD
Irinotecan—ACHE—Metabolism of proteins—MOGS—bone cancer	4.06e-05	0.0022	CbGpPWpGaD
Irinotecan—ACHE—ATF-2 transcription factor network—RB1—bone cancer	4.05e-05	0.00219	CbGpPWpGaD
Irinotecan—Angiopathy—Methotrexate—bone cancer	4.04e-05	0.00118	CcSEcCtD
Irinotecan—ALB—Folate Metabolism—DHFR—bone cancer	4.02e-05	0.00218	CbGpPWpGaD
Irinotecan—Immune system disorder—Methotrexate—bone cancer	4.02e-05	0.00118	CcSEcCtD
Irinotecan—Visual impairment—Epirubicin—bone cancer	4.01e-05	0.00117	CcSEcCtD
Irinotecan—Mediastinal disorder—Methotrexate—bone cancer	4.01e-05	0.00117	CcSEcCtD
Irinotecan—Chills—Methotrexate—bone cancer	3.99e-05	0.00117	CcSEcCtD
Irinotecan—Diarrhoea—Cisplatin—bone cancer	3.94e-05	0.00115	CcSEcCtD
Irinotecan—Alopecia—Methotrexate—bone cancer	3.93e-05	0.00115	CcSEcCtD
Irinotecan—Bradycardia—Doxorubicin—bone cancer	3.92e-05	0.00115	CcSEcCtD
Irinotecan—TOP1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.9e-05	0.00211	CbGpPWpGaD
Irinotecan—ACHE—ATF-2 transcription factor network—MMP2—bone cancer	3.88e-05	0.0021	CbGpPWpGaD
Irinotecan—Haemoglobin—Doxorubicin—bone cancer	3.87e-05	0.00113	CcSEcCtD
Irinotecan—Flushing—Epirubicin—bone cancer	3.86e-05	0.00113	CcSEcCtD
Irinotecan—Cardiac disorder—Epirubicin—bone cancer	3.86e-05	0.00113	CcSEcCtD
Irinotecan—Rhinitis—Doxorubicin—bone cancer	3.86e-05	0.00113	CcSEcCtD
Irinotecan—Haemorrhage—Doxorubicin—bone cancer	3.85e-05	0.00113	CcSEcCtD
Irinotecan—Connective tissue disorder—Doxorubicin—bone cancer	3.79e-05	0.00111	CcSEcCtD
Irinotecan—Angiopathy—Epirubicin—bone cancer	3.78e-05	0.00111	CcSEcCtD
Irinotecan—Immune system disorder—Epirubicin—bone cancer	3.76e-05	0.0011	CcSEcCtD
Irinotecan—Mediastinal disorder—Epirubicin—bone cancer	3.75e-05	0.0011	CcSEcCtD
Irinotecan—Back pain—Methotrexate—bone cancer	3.75e-05	0.0011	CcSEcCtD
Irinotecan—Chills—Epirubicin—bone cancer	3.74e-05	0.00109	CcSEcCtD
Irinotecan—Arrhythmia—Epirubicin—bone cancer	3.72e-05	0.00109	CcSEcCtD
Irinotecan—Visual impairment—Doxorubicin—bone cancer	3.71e-05	0.00109	CcSEcCtD
Irinotecan—Alopecia—Epirubicin—bone cancer	3.68e-05	0.00108	CcSEcCtD
Irinotecan—Vomiting—Cisplatin—bone cancer	3.66e-05	0.00107	CcSEcCtD
Irinotecan—Rash—Cisplatin—bone cancer	3.63e-05	0.00106	CcSEcCtD
Irinotecan—Dermatitis—Cisplatin—bone cancer	3.63e-05	0.00106	CcSEcCtD
Irinotecan—BCHE—Metabolism of proteins—MOGS—bone cancer	3.62e-05	0.00196	CbGpPWpGaD
Irinotecan—Ill-defined disorder—Methotrexate—bone cancer	3.59e-05	0.00105	CcSEcCtD
Irinotecan—Anaemia—Methotrexate—bone cancer	3.58e-05	0.00105	CcSEcCtD
Irinotecan—Flushing—Doxorubicin—bone cancer	3.58e-05	0.00105	CcSEcCtD
Irinotecan—Cardiac disorder—Doxorubicin—bone cancer	3.58e-05	0.00105	CcSEcCtD
Irinotecan—Flatulence—Epirubicin—bone cancer	3.57e-05	0.00104	CcSEcCtD
Irinotecan—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	3.54e-05	0.00192	CbGpPWpGaD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	3.54e-05	0.00192	CbGpPWpGaD
Irinotecan—ALB—Platelet degranulation—SPARC—bone cancer	3.53e-05	0.00191	CbGpPWpGaD
Irinotecan—Back pain—Epirubicin—bone cancer	3.51e-05	0.00103	CcSEcCtD
Irinotecan—Angiopathy—Doxorubicin—bone cancer	3.5e-05	0.00102	CcSEcCtD
Irinotecan—Malaise—Methotrexate—bone cancer	3.49e-05	0.00102	CcSEcCtD
Irinotecan—Muscle spasms—Epirubicin—bone cancer	3.49e-05	0.00102	CcSEcCtD
Irinotecan—Immune system disorder—Doxorubicin—bone cancer	3.48e-05	0.00102	CcSEcCtD
Irinotecan—Vertigo—Methotrexate—bone cancer	3.48e-05	0.00102	CcSEcCtD
Irinotecan—ABCC1—Arachidonic acid metabolism—PTGS2—bone cancer	3.47e-05	0.00188	CbGpPWpGaD
Irinotecan—Mediastinal disorder—Doxorubicin—bone cancer	3.47e-05	0.00102	CcSEcCtD
Irinotecan—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	3.47e-05	0.00188	CbGpPWpGaD
Irinotecan—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	3.47e-05	0.00188	CbGpPWpGaD
Irinotecan—Leukopenia—Methotrexate—bone cancer	3.47e-05	0.00101	CcSEcCtD
Irinotecan—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	3.46e-05	0.00188	CbGpPWpGaD
Irinotecan—Chills—Doxorubicin—bone cancer	3.46e-05	0.00101	CcSEcCtD
Irinotecan—Arrhythmia—Doxorubicin—bone cancer	3.44e-05	0.00101	CcSEcCtD
Irinotecan—Nausea—Cisplatin—bone cancer	3.42e-05	0.001	CcSEcCtD
Irinotecan—Alopecia—Doxorubicin—bone cancer	3.4e-05	0.000996	CcSEcCtD
Irinotecan—Cough—Methotrexate—bone cancer	3.38e-05	0.000989	CcSEcCtD
Irinotecan—Ill-defined disorder—Epirubicin—bone cancer	3.36e-05	0.000984	CcSEcCtD
Irinotecan—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	3.36e-05	0.00182	CbGpPWpGaD
Irinotecan—Anaemia—Epirubicin—bone cancer	3.35e-05	0.00098	CcSEcCtD
Irinotecan—Flatulence—Doxorubicin—bone cancer	3.31e-05	0.000967	CcSEcCtD
Irinotecan—TOP1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.27e-05	0.00177	CbGpPWpGaD
Irinotecan—Malaise—Epirubicin—bone cancer	3.27e-05	0.000956	CcSEcCtD
Irinotecan—Discomfort—Methotrexate—bone cancer	3.26e-05	0.000953	CcSEcCtD
Irinotecan—Vertigo—Epirubicin—bone cancer	3.26e-05	0.000953	CcSEcCtD
Irinotecan—Syncope—Epirubicin—bone cancer	3.25e-05	0.000951	CcSEcCtD
Irinotecan—Leukopenia—Epirubicin—bone cancer	3.24e-05	0.000949	CcSEcCtD
Irinotecan—Back pain—Doxorubicin—bone cancer	3.24e-05	0.000949	CcSEcCtD
Irinotecan—Muscle spasms—Doxorubicin—bone cancer	3.22e-05	0.000943	CcSEcCtD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	3.22e-05	0.00174	CbGpPWpGaD
Irinotecan—Confusional state—Methotrexate—bone cancer	3.19e-05	0.000932	CcSEcCtD
Irinotecan—Loss of consciousness—Epirubicin—bone cancer	3.19e-05	0.000932	CcSEcCtD
Irinotecan—Cough—Epirubicin—bone cancer	3.16e-05	0.000925	CcSEcCtD
Irinotecan—Anaphylactic shock—Methotrexate—bone cancer	3.16e-05	0.000925	CcSEcCtD
Irinotecan—TOP1—Circadian rythm related genes—TP53—bone cancer	3.14e-05	0.0017	CbGpPWpGaD
Irinotecan—Infection—Methotrexate—bone cancer	3.14e-05	0.000919	CcSEcCtD
Irinotecan—Hypertension—Epirubicin—bone cancer	3.13e-05	0.000916	CcSEcCtD
Irinotecan—Ill-defined disorder—Doxorubicin—bone cancer	3.11e-05	0.00091	CcSEcCtD
Irinotecan—SLC22A3—Transmembrane transport of small molecules—TUBB4B—bone cancer	3.11e-05	0.00168	CbGpPWpGaD
Irinotecan—Nervous system disorder—Methotrexate—bone cancer	3.1e-05	0.000907	CcSEcCtD
Irinotecan—Anaemia—Doxorubicin—bone cancer	3.1e-05	0.000907	CcSEcCtD
Irinotecan—Thrombocytopenia—Methotrexate—bone cancer	3.1e-05	0.000905	CcSEcCtD
Irinotecan—Hyperhidrosis—Methotrexate—bone cancer	3.06e-05	0.000894	CcSEcCtD
Irinotecan—Discomfort—Epirubicin—bone cancer	3.05e-05	0.000892	CcSEcCtD
Irinotecan—UGT1A1—Biological oxidations—CYP3A4—bone cancer	3.03e-05	0.00164	CbGpPWpGaD
Irinotecan—UGT1A9—Biological oxidations—CYP3A4—bone cancer	3.03e-05	0.00164	CbGpPWpGaD
Irinotecan—Malaise—Doxorubicin—bone cancer	3.02e-05	0.000885	CcSEcCtD
Irinotecan—Vertigo—Doxorubicin—bone cancer	3.01e-05	0.000882	CcSEcCtD
Irinotecan—Anorexia—Methotrexate—bone cancer	3.01e-05	0.000882	CcSEcCtD
Irinotecan—Syncope—Doxorubicin—bone cancer	3.01e-05	0.00088	CcSEcCtD
Irinotecan—Leukopenia—Doxorubicin—bone cancer	3e-05	0.000878	CcSEcCtD
Irinotecan—ACHE—ATF-2 transcription factor network—JUN—bone cancer	3e-05	0.00162	CbGpPWpGaD
Irinotecan—UGT1A1—Metapathway biotransformation—CYP3A4—bone cancer	2.98e-05	0.00162	CbGpPWpGaD
Irinotecan—UGT1A9—Metapathway biotransformation—CYP3A4—bone cancer	2.98e-05	0.00162	CbGpPWpGaD
Irinotecan—Confusional state—Epirubicin—bone cancer	2.98e-05	0.000873	CcSEcCtD
Irinotecan—Oedema—Epirubicin—bone cancer	2.96e-05	0.000865	CcSEcCtD
Irinotecan—Anaphylactic shock—Epirubicin—bone cancer	2.96e-05	0.000865	CcSEcCtD
Irinotecan—Hypotension—Methotrexate—bone cancer	2.95e-05	0.000864	CcSEcCtD
Irinotecan—UGT1A1—NRF2 pathway—GSTP1—bone cancer	2.95e-05	0.0016	CbGpPWpGaD
Irinotecan—UGT1A1—NRF2 pathway—TGFBR2—bone cancer	2.95e-05	0.0016	CbGpPWpGaD
Irinotecan—UGT1A9—NRF2 pathway—TGFBR2—bone cancer	2.95e-05	0.0016	CbGpPWpGaD
Irinotecan—UGT1A9—NRF2 pathway—GSTP1—bone cancer	2.95e-05	0.0016	CbGpPWpGaD
Irinotecan—Loss of consciousness—Doxorubicin—bone cancer	2.95e-05	0.000862	CcSEcCtD
Irinotecan—Infection—Epirubicin—bone cancer	2.94e-05	0.00086	CcSEcCtD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	2.93e-05	0.00159	CbGpPWpGaD
Irinotecan—Cough—Doxorubicin—bone cancer	2.93e-05	0.000856	CcSEcCtD
Irinotecan—Shock—Epirubicin—bone cancer	2.91e-05	0.000851	CcSEcCtD
Irinotecan—Nervous system disorder—Epirubicin—bone cancer	2.9e-05	0.000849	CcSEcCtD
Irinotecan—Thrombocytopenia—Epirubicin—bone cancer	2.9e-05	0.000847	CcSEcCtD
Irinotecan—Hypertension—Doxorubicin—bone cancer	2.9e-05	0.000847	CcSEcCtD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	2.89e-05	0.00157	CbGpPWpGaD
Irinotecan—ABCC2—NRF2 pathway—GSTP1—bone cancer	2.88e-05	0.00156	CbGpPWpGaD
Irinotecan—ABCC2—NRF2 pathway—TGFBR2—bone cancer	2.88e-05	0.00156	CbGpPWpGaD
Irinotecan—Hyperhidrosis—Epirubicin—bone cancer	2.86e-05	0.000837	CcSEcCtD
Irinotecan—Insomnia—Methotrexate—bone cancer	2.86e-05	0.000836	CcSEcCtD
Irinotecan—Paraesthesia—Methotrexate—bone cancer	2.84e-05	0.00083	CcSEcCtD
Irinotecan—Discomfort—Doxorubicin—bone cancer	2.82e-05	0.000825	CcSEcCtD
Irinotecan—Anorexia—Epirubicin—bone cancer	2.82e-05	0.000825	CcSEcCtD
Irinotecan—Dyspnoea—Methotrexate—bone cancer	2.82e-05	0.000824	CcSEcCtD
Irinotecan—Somnolence—Methotrexate—bone cancer	2.81e-05	0.000822	CcSEcCtD
Irinotecan—Dyspepsia—Methotrexate—bone cancer	2.78e-05	0.000814	CcSEcCtD
Irinotecan—Hypotension—Epirubicin—bone cancer	2.76e-05	0.000809	CcSEcCtD
Irinotecan—Confusional state—Doxorubicin—bone cancer	2.76e-05	0.000807	CcSEcCtD
Irinotecan—Decreased appetite—Methotrexate—bone cancer	2.75e-05	0.000804	CcSEcCtD
Irinotecan—Anaphylactic shock—Doxorubicin—bone cancer	2.74e-05	0.000801	CcSEcCtD
Irinotecan—Oedema—Doxorubicin—bone cancer	2.74e-05	0.000801	CcSEcCtD
Irinotecan—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	2.73e-05	0.00148	CbGpPWpGaD
Irinotecan—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	2.73e-05	0.00148	CbGpPWpGaD
Irinotecan—Gastrointestinal disorder—Methotrexate—bone cancer	2.73e-05	0.000798	CcSEcCtD
Irinotecan—Fatigue—Methotrexate—bone cancer	2.73e-05	0.000797	CcSEcCtD
Irinotecan—Infection—Doxorubicin—bone cancer	2.72e-05	0.000796	CcSEcCtD
Irinotecan—Pain—Methotrexate—bone cancer	2.7e-05	0.000791	CcSEcCtD
Irinotecan—Shock—Doxorubicin—bone cancer	2.69e-05	0.000788	CcSEcCtD
Irinotecan—Nervous system disorder—Doxorubicin—bone cancer	2.68e-05	0.000785	CcSEcCtD
Irinotecan—SLC22A3—Transmembrane transport of small molecules—TUBB2A—bone cancer	2.68e-05	0.00145	CbGpPWpGaD
Irinotecan—Thrombocytopenia—Doxorubicin—bone cancer	2.68e-05	0.000784	CcSEcCtD
Irinotecan—Insomnia—Epirubicin—bone cancer	2.68e-05	0.000783	CcSEcCtD
Irinotecan—Paraesthesia—Epirubicin—bone cancer	2.66e-05	0.000777	CcSEcCtD
Irinotecan—Hyperhidrosis—Doxorubicin—bone cancer	2.65e-05	0.000774	CcSEcCtD
Irinotecan—Dyspnoea—Epirubicin—bone cancer	2.64e-05	0.000772	CcSEcCtD
Irinotecan—Somnolence—Epirubicin—bone cancer	2.63e-05	0.000769	CcSEcCtD
Irinotecan—Anorexia—Doxorubicin—bone cancer	2.61e-05	0.000763	CcSEcCtD
Irinotecan—Feeling abnormal—Methotrexate—bone cancer	2.61e-05	0.000762	CcSEcCtD
Irinotecan—Dyspepsia—Epirubicin—bone cancer	2.6e-05	0.000762	CcSEcCtD
Irinotecan—UGT1A1—Biological oxidations—GSTP1—bone cancer	2.59e-05	0.0014	CbGpPWpGaD
Irinotecan—UGT1A9—Biological oxidations—GSTP1—bone cancer	2.59e-05	0.0014	CbGpPWpGaD
Irinotecan—Gastrointestinal pain—Methotrexate—bone cancer	2.59e-05	0.000756	CcSEcCtD
Irinotecan—Decreased appetite—Epirubicin—bone cancer	2.57e-05	0.000752	CcSEcCtD
Irinotecan—Hypotension—Doxorubicin—bone cancer	2.56e-05	0.000748	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Epirubicin—bone cancer	2.55e-05	0.000747	CcSEcCtD
Irinotecan—UGT1A1—Metapathway biotransformation—GSTP1—bone cancer	2.55e-05	0.00138	CbGpPWpGaD
Irinotecan—UGT1A9—Metapathway biotransformation—GSTP1—bone cancer	2.55e-05	0.00138	CbGpPWpGaD
Irinotecan—Fatigue—Epirubicin—bone cancer	2.55e-05	0.000746	CcSEcCtD
Irinotecan—CYP3A7—Biological oxidations—CYP3A4—bone cancer	2.55e-05	0.00138	CbGpPWpGaD
Irinotecan—ABCG2—Fluoropyrimidine Activity—TP53—bone cancer	2.54e-05	0.00137	CbGpPWpGaD
Irinotecan—Pain—Epirubicin—bone cancer	2.53e-05	0.00074	CcSEcCtD
Irinotecan—Constipation—Epirubicin—bone cancer	2.53e-05	0.00074	CcSEcCtD
Irinotecan—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	2.51e-05	0.00136	CbGpPWpGaD
Irinotecan—Body temperature increased—Methotrexate—bone cancer	2.5e-05	0.000731	CcSEcCtD
Irinotecan—Abdominal pain—Methotrexate—bone cancer	2.5e-05	0.000731	CcSEcCtD
Irinotecan—Insomnia—Doxorubicin—bone cancer	2.48e-05	0.000724	CcSEcCtD
Irinotecan—Paraesthesia—Doxorubicin—bone cancer	2.46e-05	0.000719	CcSEcCtD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	2.45e-05	0.00133	CbGpPWpGaD
Irinotecan—Dyspnoea—Doxorubicin—bone cancer	2.44e-05	0.000714	CcSEcCtD
Irinotecan—Feeling abnormal—Epirubicin—bone cancer	2.44e-05	0.000713	CcSEcCtD
Irinotecan—Somnolence—Doxorubicin—bone cancer	2.43e-05	0.000712	CcSEcCtD
Irinotecan—SLC22A3—Metabolism—NDUFA12—bone cancer	2.43e-05	0.00132	CbGpPWpGaD
Irinotecan—Gastrointestinal pain—Epirubicin—bone cancer	2.42e-05	0.000708	CcSEcCtD
Irinotecan—Dyspepsia—Doxorubicin—bone cancer	2.41e-05	0.000705	CcSEcCtD
Irinotecan—Decreased appetite—Doxorubicin—bone cancer	2.38e-05	0.000696	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Doxorubicin—bone cancer	2.36e-05	0.000691	CcSEcCtD
Irinotecan—Fatigue—Doxorubicin—bone cancer	2.36e-05	0.00069	CcSEcCtD
Irinotecan—Constipation—Doxorubicin—bone cancer	2.34e-05	0.000685	CcSEcCtD
Irinotecan—Pain—Doxorubicin—bone cancer	2.34e-05	0.000685	CcSEcCtD
Irinotecan—Abdominal pain—Epirubicin—bone cancer	2.34e-05	0.000684	CcSEcCtD
Irinotecan—Body temperature increased—Epirubicin—bone cancer	2.34e-05	0.000684	CcSEcCtD
Irinotecan—Hypersensitivity—Methotrexate—bone cancer	2.33e-05	0.000681	CcSEcCtD
Irinotecan—Asthenia—Methotrexate—bone cancer	2.27e-05	0.000664	CcSEcCtD
Irinotecan—ABCC2—Transmembrane transport of small molecules—TUBB4B—bone cancer	2.26e-05	0.00123	CbGpPWpGaD
Irinotecan—Feeling abnormal—Doxorubicin—bone cancer	2.26e-05	0.00066	CcSEcCtD
Irinotecan—Gastrointestinal pain—Doxorubicin—bone cancer	2.24e-05	0.000655	CcSEcCtD
Irinotecan—ABCC1—Transmembrane transport of small molecules—TUBB4B—bone cancer	2.24e-05	0.00121	CbGpPWpGaD
Irinotecan—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	2.23e-05	0.00121	CbGpPWpGaD
Irinotecan—ACHE—Metabolism of proteins—TUBB4B—bone cancer	2.22e-05	0.0012	CbGpPWpGaD
Irinotecan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	2.21e-05	0.0012	CbGpPWpGaD
Irinotecan—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	2.21e-05	0.0012	CbGpPWpGaD
Irinotecan—Hypersensitivity—Epirubicin—bone cancer	2.18e-05	0.000638	CcSEcCtD
Irinotecan—CYP3A7—Biological oxidations—GSTP1—bone cancer	2.18e-05	0.00118	CbGpPWpGaD
Irinotecan—Abdominal pain—Doxorubicin—bone cancer	2.16e-05	0.000633	CcSEcCtD
Irinotecan—Body temperature increased—Doxorubicin—bone cancer	2.16e-05	0.000633	CcSEcCtD
Irinotecan—Diarrhoea—Methotrexate—bone cancer	2.16e-05	0.000633	CcSEcCtD
Irinotecan—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	2.15e-05	0.00116	CbGpPWpGaD
Irinotecan—SLCO1B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	2.13e-05	0.00115	CbGpPWpGaD
Irinotecan—Asthenia—Epirubicin—bone cancer	2.12e-05	0.000621	CcSEcCtD
Irinotecan—Dizziness—Methotrexate—bone cancer	2.09e-05	0.000612	CcSEcCtD
Irinotecan—Diarrhoea—Epirubicin—bone cancer	2.02e-05	0.000592	CcSEcCtD
Irinotecan—Hypersensitivity—Doxorubicin—bone cancer	2.02e-05	0.00059	CcSEcCtD
Irinotecan—SLC22A3—Metabolism—NT5C3A—bone cancer	2.01e-05	0.00109	CbGpPWpGaD
Irinotecan—Vomiting—Methotrexate—bone cancer	2.01e-05	0.000588	CcSEcCtD
Irinotecan—Rash—Methotrexate—bone cancer	1.99e-05	0.000583	CcSEcCtD
Irinotecan—Dermatitis—Methotrexate—bone cancer	1.99e-05	0.000583	CcSEcCtD
Irinotecan—BCHE—Metabolism of proteins—TUBB4B—bone cancer	1.98e-05	0.00107	CbGpPWpGaD
Irinotecan—Headache—Methotrexate—bone cancer	1.98e-05	0.000579	CcSEcCtD
Irinotecan—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	1.97e-05	0.00107	CbGpPWpGaD
Irinotecan—Asthenia—Doxorubicin—bone cancer	1.96e-05	0.000575	CcSEcCtD
Irinotecan—Dizziness—Epirubicin—bone cancer	1.96e-05	0.000572	CcSEcCtD
Irinotecan—ABCC2—Transmembrane transport of small molecules—TUBB2A—bone cancer	1.95e-05	0.00106	CbGpPWpGaD
Irinotecan—ABCC1—Transmembrane transport of small molecules—TUBB2A—bone cancer	1.93e-05	0.00105	CbGpPWpGaD
Irinotecan—ACHE—Metabolism of proteins—TUBB2A—bone cancer	1.92e-05	0.00104	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—NDUFA12—bone cancer	1.91e-05	0.00104	CbGpPWpGaD
Irinotecan—CYP2B6—Biological oxidations—CYP3A4—bone cancer	1.88e-05	0.00102	CbGpPWpGaD
Irinotecan—Vomiting—Epirubicin—bone cancer	1.88e-05	0.00055	CcSEcCtD
Irinotecan—Nausea—Methotrexate—bone cancer	1.88e-05	0.000549	CcSEcCtD
Irinotecan—Diarrhoea—Doxorubicin—bone cancer	1.87e-05	0.000548	CcSEcCtD
Irinotecan—Rash—Epirubicin—bone cancer	1.87e-05	0.000546	CcSEcCtD
Irinotecan—Dermatitis—Epirubicin—bone cancer	1.86e-05	0.000545	CcSEcCtD
Irinotecan—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	1.86e-05	0.00101	CbGpPWpGaD
Irinotecan—Headache—Epirubicin—bone cancer	1.85e-05	0.000542	CcSEcCtD
Irinotecan—CYP3A5—Biological oxidations—CYP3A4—bone cancer	1.84e-05	0.000996	CbGpPWpGaD
Irinotecan—SLCO1B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	1.84e-05	0.000994	CbGpPWpGaD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	1.82e-05	0.000985	CbGpPWpGaD
Irinotecan—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	1.81e-05	0.000983	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—NDUFA12—bone cancer	1.81e-05	0.000982	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—NDUFA12—bone cancer	1.81e-05	0.000982	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	1.81e-05	0.00098	CbGpPWpGaD
Irinotecan—Dizziness—Doxorubicin—bone cancer	1.81e-05	0.00053	CcSEcCtD
Irinotecan—Nausea—Epirubicin—bone cancer	1.76e-05	0.000514	CcSEcCtD
Irinotecan—ABCC1—Metabolism—NDUFA12—bone cancer	1.75e-05	0.000947	CbGpPWpGaD
Irinotecan—Vomiting—Doxorubicin—bone cancer	1.74e-05	0.000509	CcSEcCtD
Irinotecan—Rash—Doxorubicin—bone cancer	1.73e-05	0.000505	CcSEcCtD
Irinotecan—Dermatitis—Doxorubicin—bone cancer	1.72e-05	0.000504	CcSEcCtD
Irinotecan—Headache—Doxorubicin—bone cancer	1.71e-05	0.000502	CcSEcCtD
Irinotecan—BCHE—Metabolism of proteins—TUBB2A—bone cancer	1.71e-05	0.000927	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—NDUFA12—bone cancer	1.71e-05	0.000923	CbGpPWpGaD
Irinotecan—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	1.7e-05	0.00092	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—NDUFA12—bone cancer	1.66e-05	0.0009	CbGpPWpGaD
Irinotecan—Nausea—Doxorubicin—bone cancer	1.63e-05	0.000476	CcSEcCtD
Irinotecan—CYP2B6—Biological oxidations—GSTP1—bone cancer	1.61e-05	0.000872	CbGpPWpGaD
Irinotecan—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	1.59e-05	0.00086	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—NT5C3A—bone cancer	1.58e-05	0.000858	CbGpPWpGaD
Irinotecan—CYP3A5—Biological oxidations—GSTP1—bone cancer	1.57e-05	0.000852	CbGpPWpGaD
Irinotecan—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	1.56e-05	0.000847	CbGpPWpGaD
Irinotecan—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	1.55e-05	0.00084	CbGpPWpGaD
Irinotecan—ACHE—Transmission across Chemical Synapses—BRAF—bone cancer	1.55e-05	0.00084	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	1.54e-05	0.000834	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—NDUFA12—bone cancer	1.54e-05	0.000833	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—NDUFA12—bone cancer	1.53e-05	0.000826	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—NT5C3A—bone cancer	1.5e-05	0.000814	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—NT5C3A—bone cancer	1.5e-05	0.000814	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—NT5C3A—bone cancer	1.45e-05	0.000785	CbGpPWpGaD
Irinotecan—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	1.43e-05	0.000774	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—NT5C3A—bone cancer	1.41e-05	0.000765	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	1.4e-05	0.000759	CbGpPWpGaD
Irinotecan—BCHE—Transmission across Chemical Synapses—BRAF—bone cancer	1.38e-05	0.000749	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—NT5C3A—bone cancer	1.38e-05	0.000746	CbGpPWpGaD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	1.35e-05	0.00073	CbGpPWpGaD
Irinotecan—ACHE—Metabolism of proteins—EIF2S1—bone cancer	1.34e-05	0.000724	CbGpPWpGaD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	1.3e-05	0.000704	CbGpPWpGaD
Irinotecan—ACHE—Transmission across Chemical Synapses—MDM2—bone cancer	1.3e-05	0.000704	CbGpPWpGaD
Irinotecan—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	1.3e-05	0.000702	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	1.28e-05	0.000691	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—NT5C3A—bone cancer	1.28e-05	0.000691	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—NT5C3A—bone cancer	1.26e-05	0.000684	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	1.26e-05	0.000682	CbGpPWpGaD
Irinotecan—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	1.21e-05	0.000658	CbGpPWpGaD
Irinotecan—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	1.2e-05	0.00065	CbGpPWpGaD
Irinotecan—BCHE—Metabolism of proteins—EIF2S1—bone cancer	1.19e-05	0.000646	CbGpPWpGaD
Irinotecan—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	1.19e-05	0.000646	CbGpPWpGaD
Irinotecan—ACHE—Neuronal System—BRAF—bone cancer	1.19e-05	0.000643	CbGpPWpGaD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.17e-05	0.000634	CbGpPWpGaD
Irinotecan—BCHE—Transmission across Chemical Synapses—MDM2—bone cancer	1.16e-05	0.000628	CbGpPWpGaD
Irinotecan—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	1.13e-05	0.000611	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—NDUFA12—bone cancer	1.13e-05	0.000611	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—NDUFA12—bone cancer	1.1e-05	0.000597	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	1.07e-05	0.000578	CbGpPWpGaD
Irinotecan—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	1.06e-05	0.000576	CbGpPWpGaD
Irinotecan—BCHE—Neuronal System—BRAF—bone cancer	1.06e-05	0.000574	CbGpPWpGaD
Irinotecan—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	1.05e-05	0.000568	CbGpPWpGaD
Irinotecan—ACHE—Neuronal System—MDM2—bone cancer	9.96e-06	0.000539	CbGpPWpGaD
Irinotecan—ALB—Metabolism—NDUFA12—bone cancer	9.5e-06	0.000514	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—NT5C3A—bone cancer	9.35e-06	0.000506	CbGpPWpGaD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	9.21e-06	0.000499	CbGpPWpGaD
Irinotecan—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.19e-06	0.000497	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—NT5C3A—bone cancer	9.14e-06	0.000495	CbGpPWpGaD
Irinotecan—ALB—Folate Metabolism—TP53—bone cancer	8.99e-06	0.000487	CbGpPWpGaD
Irinotecan—BCHE—Neuronal System—MDM2—bone cancer	8.88e-06	0.000481	CbGpPWpGaD
Irinotecan—SLC22A3—Metabolism—ENO2—bone cancer	8.82e-06	0.000477	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—NDUFA12—bone cancer	8.32e-06	0.000451	CbGpPWpGaD
Irinotecan—SLC22A3—Metabolism—DHFR—bone cancer	8.18e-06	0.000443	CbGpPWpGaD
Irinotecan—ALB—Hemostasis—SPARC—bone cancer	8.06e-06	0.000436	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	7.92e-06	0.000429	CbGpPWpGaD
Irinotecan—ALB—Metabolism—NT5C3A—bone cancer	7.87e-06	0.000426	CbGpPWpGaD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	7.74e-06	0.000419	CbGpPWpGaD
Irinotecan—SLC22A3—Metabolism—GNA11—bone cancer	7.64e-06	0.000414	CbGpPWpGaD
Irinotecan—ABCC1—Disease—ENO2—bone cancer	7.58e-06	0.00041	CbGpPWpGaD
Irinotecan—ALB—Hemostasis—GNA11—bone cancer	7.37e-06	0.000399	CbGpPWpGaD
Irinotecan—CYP3A4—Biological oxidations—GSTP1—bone cancer	7.32e-06	0.000396	CbGpPWpGaD
Irinotecan—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	7.22e-06	0.000391	CbGpPWpGaD
Irinotecan—ABCC1—Disease—DHFR—bone cancer	7.03e-06	0.000381	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—ENO2—bone cancer	6.94e-06	0.000376	CbGpPWpGaD
Irinotecan—SLC22A3—Metabolism—CYP3A4—bone cancer	6.93e-06	0.000375	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—NT5C3A—bone cancer	6.9e-06	0.000373	CbGpPWpGaD
Irinotecan—ALB—Hemostasis—IL3—bone cancer	6.68e-06	0.000362	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—ENO2—bone cancer	6.58e-06	0.000357	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—ENO2—bone cancer	6.58e-06	0.000357	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—DHFR—bone cancer	6.44e-06	0.000349	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—ENO2—bone cancer	6.35e-06	0.000344	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—ENO2—bone cancer	6.19e-06	0.000335	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—DHFR—bone cancer	6.11e-06	0.000331	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—DHFR—bone cancer	6.11e-06	0.000331	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—ENO2—bone cancer	6.03e-06	0.000327	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—GNA11—bone cancer	6.02e-06	0.000326	CbGpPWpGaD
Irinotecan—SLC22A3—Metabolism—GSTP1—bone cancer	5.93e-06	0.000321	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—DHFR—bone cancer	5.89e-06	0.000319	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	5.87e-06	0.000318	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—DHFR—bone cancer	5.74e-06	0.000311	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—GNA11—bone cancer	5.71e-06	0.000309	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—GNA11—bone cancer	5.71e-06	0.000309	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	5.66e-06	0.000306	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—DHFR—bone cancer	5.6e-06	0.000303	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—ENO2—bone cancer	5.59e-06	0.000302	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—ENO2—bone cancer	5.54e-06	0.0003	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—GNA11—bone cancer	5.5e-06	0.000298	CbGpPWpGaD
Irinotecan—ACHE—Metabolism of proteins—MMP2—bone cancer	5.47e-06	0.000296	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—CYP3A4—bone cancer	5.45e-06	0.000295	CbGpPWpGaD
Irinotecan—ACHE—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.43e-06	0.000294	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—GNA11—bone cancer	5.37e-06	0.000291	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—GNA11—bone cancer	5.23e-06	0.000283	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—DHFR—bone cancer	5.18e-06	0.000281	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—CYP3A4—bone cancer	5.18e-06	0.00028	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—CYP3A4—bone cancer	5.18e-06	0.00028	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.15e-06	0.000279	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—DHFR—bone cancer	5.14e-06	0.000278	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—NDUFA12—bone cancer	5.13e-06	0.000278	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	5.1e-06	0.000276	CbGpPWpGaD
Irinotecan—ABCC1—Disease—TGFBR2—bone cancer	5.1e-06	0.000276	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—CYP3A4—bone cancer	4.99e-06	0.00027	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.97e-06	0.000269	CbGpPWpGaD
Irinotecan—BCHE—Metabolism of proteins—MMP2—bone cancer	4.88e-06	0.000264	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—CYP3A4—bone cancer	4.87e-06	0.000263	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—GNA11—bone cancer	4.84e-06	0.000262	CbGpPWpGaD
Irinotecan—BCHE—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.84e-06	0.000262	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—GNA11—bone cancer	4.8e-06	0.00026	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—CYP3A4—bone cancer	4.74e-06	0.000257	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.72e-06	0.000255	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—GSTP1—bone cancer	4.67e-06	0.000253	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—GSTP1—bone cancer	4.43e-06	0.00024	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—GSTP1—bone cancer	4.43e-06	0.00024	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—CYP3A4—bone cancer	4.39e-06	0.000238	CbGpPWpGaD
Irinotecan—ALB—Hemostasis—PLAU—bone cancer	4.38e-06	0.000237	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—CYP3A4—bone cancer	4.35e-06	0.000236	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—GSTP1—bone cancer	4.27e-06	0.000231	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—NT5C3A—bone cancer	4.25e-06	0.00023	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—GSTP1—bone cancer	4.16e-06	0.000225	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—ENO2—bone cancer	4.1e-06	0.000222	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—GSTP1—bone cancer	4.06e-06	0.00022	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.01e-06	0.000217	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—ENO2—bone cancer	4e-06	0.000217	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—DHFR—bone cancer	3.8e-06	0.000206	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—GSTP1—bone cancer	3.76e-06	0.000203	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—GSTP1—bone cancer	3.72e-06	0.000202	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—DHFR—bone cancer	3.71e-06	0.000201	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—GNA11—bone cancer	3.55e-06	0.000192	CbGpPWpGaD
Irinotecan—ABCC1—Disease—KIT—bone cancer	3.48e-06	0.000188	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—GNA11—bone cancer	3.47e-06	0.000188	CbGpPWpGaD
Irinotecan—ALB—Metabolism—ENO2—bone cancer	3.45e-06	0.000187	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.37e-06	0.000182	CbGpPWpGaD
Irinotecan—ABCC1—Disease—BRAF—bone cancer	3.27e-06	0.000177	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—CYP3A4—bone cancer	3.22e-06	0.000174	CbGpPWpGaD
Irinotecan—ALB—Metabolism—DHFR—bone cancer	3.2e-06	0.000173	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—CYP3A4—bone cancer	3.15e-06	0.00017	CbGpPWpGaD
Irinotecan—SLC22A3—Metabolism—PTGS2—bone cancer	3.07e-06	0.000166	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—ENO2—bone cancer	3.02e-06	0.000164	CbGpPWpGaD
Irinotecan—ALB—Metabolism—GNA11—bone cancer	2.99e-06	0.000162	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—DHFR—bone cancer	2.8e-06	0.000152	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—GSTP1—bone cancer	2.75e-06	0.000149	CbGpPWpGaD
Irinotecan—ABCC1—Disease—MDM2—bone cancer	2.74e-06	0.000148	CbGpPWpGaD
Irinotecan—ALB—Metabolism—CYP3A4—bone cancer	2.71e-06	0.000147	CbGpPWpGaD
Irinotecan—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.7e-06	0.000146	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—GSTP1—bone cancer	2.69e-06	0.000146	CbGpPWpGaD
Irinotecan—ABCC1—Disease—PTGS2—bone cancer	2.64e-06	0.000143	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—GNA11—bone cancer	2.62e-06	0.000142	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—PTGS2—bone cancer	2.42e-06	0.000131	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—CYP3A4—bone cancer	2.37e-06	0.000129	CbGpPWpGaD
Irinotecan—ALB—Metabolism—GSTP1—bone cancer	2.32e-06	0.000125	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—PTGS2—bone cancer	2.29e-06	0.000124	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—PTGS2—bone cancer	2.29e-06	0.000124	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—PTGS2—bone cancer	2.21e-06	0.00012	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—PTGS2—bone cancer	2.16e-06	0.000117	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—PTGS2—bone cancer	2.1e-06	0.000114	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—GSTP1—bone cancer	2.03e-06	0.00011	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—PTGS2—bone cancer	1.95e-06	0.000105	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—PTGS2—bone cancer	1.93e-06	0.000104	CbGpPWpGaD
Irinotecan—ABCC1—Disease—EGFR—bone cancer	1.87e-06	0.000101	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—ENO2—bone cancer	1.86e-06	0.000101	CbGpPWpGaD
Irinotecan—ALB—Hemostasis—TP53—bone cancer	1.76e-06	9.54e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—DHFR—bone cancer	1.73e-06	9.35e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—GNA11—bone cancer	1.61e-06	8.74e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—PTGS2—bone cancer	1.43e-06	7.72e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—PTGS2—bone cancer	1.39e-06	7.55e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—GSTP1—bone cancer	1.25e-06	6.77e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—PTGS2—bone cancer	1.2e-06	6.5e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—PTGS2—bone cancer	1.05e-06	5.7e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—PTGS2—bone cancer	6.48e-07	3.51e-05	CbGpPWpGaD
